Wells Fargo & Company Autolus Therapeutics PLC Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AUTL
# of Institutions
116Shares Held
166MCall Options Held
34.2KPut Options Held
19.5K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$86.2 Million86.45% of portfolio
-
Blackstone Inc New York, NY20.5MShares$82.8 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA17.9MShares$72.3 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$61.7 Million1.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$49.9 Million0.59% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $367M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...